Cingulate Inc.: extends trial period for Matthew N. Brams to Dec 31, 2026

What happened Cingulate Inc reported that on Sep 30, 2026 its wholly owned subsidiary Cingulate Therapeutics LLC entered into amendment No. 2 to the employment agreement with Matthew N. Brams, executive vice president and chief medical officer, effective Jan 1, 2026. Pursuant to the amendment, the trial period for Mr. Brams’ full-time employment was extended from Sep 30, 2026 to Dec 31, 2026.

Key details

• Amendment No. 2 was entered into on Sep 30, 2026 and is described as effective Jan 1, 2026.
• The trial period extension moves the end date from Sep 30, 2026 to Dec 31, 2026.
• Mr. Brams holds the titles executive vice president and chief medical officer.
• The action was taken by Cingulate Therapeutics LLC, a wholly owned subsidiary of Cingulate Inc.

Why it may matter The filing reports Item 5.02 (departure or election of directors or certain officers; appointment of certain officers; compensatory arrangements of certain officers), and it covers an amendment to an employment agreement that changes the trial period for a named officer. A filing does not show why the insider traded or why the company acted.